BIOSENIC, a clinical-stage company specializing in severe autoimmune and inflammatory diseases and cell therapy, along with its subsidiary Medsenic SAS, has filed a continuation patent application US 18/763,376 with the United States

Roche announced today that the US Food and Drug Administration has approved the Vabysmo® 6.0 mg single-dose prefilled syringe for treating neovascular age-related macular degeneration, diabetic macular edema

Beacon Therapeutics, a prominent player in ophthalmic gene therapy focused on restoring vision in patients with severe retinal diseases, has successfully raised $170 million in Series B funding.

Gyre Therapeutics, a biotechnology firm focusing on chronic organ diseases, announced today that the National Medical Products Administration of China has approved Gyre Pharmaceuticals’ avatrombopag maleate tablets.

Senti Biosciences, Inc. announced today that it has received an $8 million grant from the California Institute for Regenerative Medicine to advance its Phase 1 clinical trial of SENTI-202. This innovative therapy,

Sandoz has received FDA approval for Pyzchiva®, a biosimilar developed by Samsung Bioepis Co., Ltd. The approval includes formulations for subcutaneous injection and intravenous infusion

Soleno Therapeutics, Inc. has submitted a New Drug Application to the U.S. Food and Drug Administration for approval of DCCR extended-release tablets.

KBio has announced that the FDA has cleared its investigational new drug application for EV68-228-N, a human monoclonal IgG1 antibody targeting enterovirus D68 capsid. This antibody is intended for intravenous treatment of acute flaccid myelitis

Arch Biopartners Inc. has announced a significant advancement in its development of cilastatin, a drug candidate designed to prevent acute kidney injury

Concerto Biosciences, based in Cambridge, announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application to begin Phase 1 trials of Ensemble No.2